Orion Pharma (DHA:ORIONPHARM) LT-Debt-to-Total-Asset: 0.47 (As of Mar. 2026)

What is Orion Pharma LT-Debt-to-Total-Asset?

Orion Pharma DHA:ORIONPHARM +3.02% 71 LT-Debt-to-Total-Asset is 0.47 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.19 (Significantly Overvalued). The stock has 8 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Orion Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.47.

Orion Pharma's long-term debt to total assets ratio increased from Mar. 2025 (0.42) to Mar. 2026 (0.47). It may suggest that Orion Pharma is progressively becoming more dependent on debt to grow their business.

Orion Pharma (DHA:ORIONPHARM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Orion Pharma LT-Debt-to-Total-Asset Related Terms

Orion Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Orion Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma LT-Debt-to-Total-Asset Chart

Orion Pharma Annual Data

Trend

Dec14

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.38

0.37

0.41

0.43

0.45

Orion Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.42	0.45	0.45	0.46	0.47

71GF Score

Orion Pharma Ltd DHA:ORIONPHARM

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Orion Pharma LT-Debt-to-Total-Asset Calculation

Orion Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )	/	Total Assets (A: Jun. 2025 )
	=	25168.304	/	55796.148
	=	0.45

Orion Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	26615.494	/	57143.737
	=	0.47

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.47 mean?

Orion Pharma (DHA:ORIONPHARM) has a LT-Debt-to-Total-Asset of 0.47 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orion Pharma and its competitors.

Is Orion Pharma's LT-Debt-to-Total-Asset too high?

Orion Pharma's current LT-Debt-to-Total-Asset is 0.47. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Orion Pharma's LT-Debt-to-Total-Asset compare to CEG and VST?

Orion Pharma's LT-Debt-to-Total-Asset of 0.47 can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for an Utilities - Independent Power Producers company?

A good LT-Debt-to-Total-Asset depends on the Utilities - Independent Power Producers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orion Pharma and its competitors. Orion Pharma's current LT-Debt-to-Total-Asset is 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Orion Pharma stock overvalued right now?

Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.19, compared to a current price of BDT30.70 — trading 52.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.47. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current LT-Debt-to-Total-Asset is 0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT30.70 is trading 52.1% above its estimated GF Value™ of BDT20.19. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

LT-Debt-to-Total-Asset: 0.47
GF Value™: BDT20.19 vs. price of BDT30.70 (52.1% above fair value)
GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Industry Utilities Utilities - Independent Power Producers

Comparable Companies DHA:SPCL CEG VST BOM:533096 NRG BKK:GULF HKSE:01816 TLN BOM:539254 HKSE:00006 SHSE:601991 SHSE:600011 BOM:500400 HKSE:00836 NSE:JSWENERGY LSE:CNA SHSE:600023 XTAE:OPCE SHSE:600674 OKLO

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208

Website https://www.orionpharmabd.com

Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.

71GF Score

Get the complete analysis for DHA:ORIONPHARM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT30.70

Price

BDT20.19

GF Value

View DHA:ORIONPHARM Analysis

See LT-Debt-to-Total-Asset data for all stocks →